Proapoptotic chemotherapeutic drugs induce noncanonical processing and release of IL-1β via caspase-8 in dendritic cells

Journal of Immunology

Volumn 191, Issue 9, 2013, Pages 4789-4803

  Antonopoulos, Christina ^a   El Sanadi, Caroline ^a   Kaiser, William J ^b   Mocarski, Edward S ^b   Dubyak, George R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CRYOPYRIN; DOXORUBICIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; PROTEIN ASC; PROTEIN NLRC4; REGULATOR PROTEIN; STAUROSPORINE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; APOPTOSIS REGULATORY PROTEIN; BIRC2 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; CARRIER PROTEIN; CASP11 PROTEIN, MOUSE; CASPASE; CASPASE INHIBITOR; CIAS1 PROTEIN, MOUSE; CYTOSKELETON PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; IPAF PROTEIN, MOUSE; LIPOPOLYSACCHARIDE; PYCARD PROTEIN, MOUSE; TLR4 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DOWN REGULATION; ENZYME ACTIVATION; ENZYME MECHANISM; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE; AGONISTS; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DEFICIENCY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NEOPLASM;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS REGULATORY PROTEINS; CALCIUM-BINDING PROTEINS; CARRIER PROTEINS; CASPASE 1; CASPASE 8; CASPASE INHIBITORS; CASPASES; CYTOSKELETAL PROTEINS; DENDRITIC CELLS; DOXORUBICIN; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS; STAUROSPORINE; TOLL-LIKE RECEPTOR 4;

EID: 84885966098     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300645     Document Type: Article

References (61)

1. Casares, N., M. O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux, N. Chaput, E. Schmitt, A. Hamai, S. Hervas-Stubbs, M. Obeid, et al. 2005. Caspasedependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202: 1691-1701.
2. Tesniere, A., F. Schlemmer, V. Boige, O. Kepp, I. Martins, F. Ghiringhelli, L. Aymeric, M. Michaud, L. Apetoh, L. Barault, et al. 2010. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29: 482-491.
3. Rathinam, V. A., S. K. Vanaja, and K. A. Fitzgerald. 2012. Regulation of inflammasome signaling. Nat. Immunol. 13: 333-342.
4. Shimada, K., T. R. Crother, J. Karlin, J. Dagvadorj, N. Chiba, S. Chen, V. K. Ramanujan, A. J. Wolf, L. Vergnes, D. M. Ojcius, et al. 2012. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36: 401-414.
5. Perregaux, D., and C. A. Gabel. 1994. Interleukin-1 beta maturation and release in response to ATP and nigericin: evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem. 269: 15195-15203.
6. Mariathasan, S., D. S. Weiss, K. Newton, J. McBride, K. O'Rourke, M. RooseGirma, W. P. Lee, Y. Weinrauch, D. M. Monack, and V. M. Dixit. 2006. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 440: 228-232.
7. Muñoz-Planillo, R., P. Kuffa, G. Martínez-Colón, B. L. Smith, T. M. Rajendiran, and G. Núñez. 2013. K efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity 38: 1142-1153.
8. Schroder, K., and J. Tschopp. 2010. The inflammasomes. Cell 140: 821-832.
9. Juliana, C., T. Fernandes-Alnemri, S. Kang, A. Farias, F. Qin, and E. S. Alnemri. 2012. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J. Biol. Chem. 287: 36617-36622.
10. Py, B. F., M. S. Kim, H. Vakifahmetoglu-Norberg, and J. Yuan. 2013. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol. Cell 49: 331-338.
11. Lopez-Castejon, G., N. M. Luheshi, V. Compan, S. High, R. C. Whitehead, S. Flitsch, A. Kirov, I. Prudovsky, E. Swanton, and D. Brough. 2013. Deubiquitinases regulate the activity of caspase-1 and interleukin-1β secretion via assembly of the inflammasome. J. Biol. Chem. 288: 2721-2733.
12. Ghiringhelli, F., L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, et al. 2009. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat. Med. 15: 1170-1178.
13. Bruchard, M., G. Mignot, V. Derangère, F. Chalmin, A. Chevriaux, F. Végran, W. Boireau, B. Simon, B. Ryffel, J. L. Connat, et al 2013. Chemotherapytriggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19: 57-64.
14. Sauter, K. A. D., L. J. Wood, J. Wong, M. Iordanov, and B. E. Magun. 2011. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol. Ther. 11: 1008-1016.
15. Gringhuis, S. I., T. M. Kaptein, B. A. Wevers, B. Theelen, M. van der Vlist, T. Boekhout, and T. B. Geijtenbeek. 2012. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome. Nat. Immunol. 13: 246-254.
16. Maelfait, J., E. Vercammen, S. Janssens, P. Schotte, M. Haegman, S. Magez, and R. Beyaert. 2008. Stimulation of Toll-like receptor 3 and 4 induces interleukin1beta maturation by caspase-8. J. Exp. Med. 205: 1967-1973.
17. Vince, J. E., W. W. L. Wong, I. Gentle, K. E. Lawlor, R. Allam, L. O'Reilly, K. Mason, O. Gross, S. Ma, G. Guarda, et al. 2012. Inhibitor of apoptosis proteins limit RIP3 kinase-dependent interleukin-1 activation. Immunity 36: 215-227.
18. Bossaller, L., P. I. Chiang, C. Schmidt-Lauber, S. Ganesan, W. J. Kaiser, V. A. Rathinam, E. S. Mocarski, D. Subramanian, D. R. Green, N. Silverman, et al. 2012. Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner. J. Immunol. 189: 5508-5512.
19. Uchiyama, R., S. Yonehara, and H. Tsutsui. 2013. Fas-mediated inflammatory response in Listeria monocytogenes infection. J. Immunol. 190: 4245-4254.
20. Mocarski, E. S., J. W. Upton, and W. J. Kaiser. 2012. Viral infection and the evolution of caspase 8-regulated apoptotic and necrotic death pathways. Nat. Rev. Immunol. 12: 79-88.
21. Qu, Y., L. Ramachandra, S. Mohr, L. Franchi, C. V. Harding, G. Nunez, and G. R. Dubyak. 2009. P2X7 receptor-stimulated secretion of MHC class IIcontaining exosomes requires the ASC/NLRP3 inflammasome but is independent of caspase-1. J. Immunol. 182: 5052-5062.
22. Kayagaki, N., S. Warming, M. Lamkanfi, L. Vande Walle, S. Louie, J. Dong, K. Newton, Y. Qu, J. F. Liu, S. Heldens, et al. 2011. Non-canonical inflammasome activation targets caspase-11. Nature 479: 117-121.
23. Li, P., H. Allen, S. Banerjee, S. Franklin, L. Herzog, C. Johnston, J. McDowell, M. Paskind, L. Rodman, J. Salfeld, et al. 1995. Mice deficient in IL-1 betaconverting enzyme are defective in production of mature IL-1 beta and resistant to endotoxic shock. Cell 80: 401-411.
24. Kaiser, W. J., J. W. Upton, A. B. Long, D. Livingston-Rosanoff, L. P. Daley-Bauer, R. Hakem, T. Caspary, and E. S. Mocarski. 2011. RIP3 mediates the embryonic lethality of caspase-8-deficient mice. Nature 471: 368-372.
25. Stoll, S., J. Delon, T. M. Brotz, and R. N. Germain. 2002. Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 296: 1873-1876.
26. Lapenna, S., and A. Giordano. 2009. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8: 547-566.
27. Gescher, A. 2000. Staurosporine analogues: pharmacological toys or useful antitumour agents? Crit. Rev. Oncol. Hematol. 34: 127-135.
28. Marti, G. E., M. Stetler-Stevenson, N. D. Grant, T. White, W. D. Figg, T. Tohnya, E. S. Jaffe, K. Dunleavy, J. E. Janik, S. M. Steinberg, and W. H. Wilson. 2011. Phase I trial of 7-hydroxystaurosporine and fludararbine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. Leuk. Lymphoma 52: 2284-2292.
29. Jimeno, A., M. A. Rudek, T. Purcell, D. A. Laheru, W. A. Messersmith, J. Dancey, M. A. Carducci, S. D. Baker, M. Hidalgo, and R. C. Donehower. 2008. Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. Cancer Chemother. Pharmacol. 61: 423-433.
30. Pelegrin, P., C. Barroso-Gutierrez, and A. Surprenant. 2008. P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage. J. Immunol. 180: 7147-7157.
31. Verhoef, P. A., S. B. Kertesy, K. Lundberg, J. M. Kahlenberg, and G. R. Dubyak. 2005. Inhibitory effects of chloride on the activation of caspase-1, IL-1beta secretion, and cytolysis by the P2X7 receptor. J. Immunol. 175: 7623-7634.
32. He, S., Y. Liang, F. Shao, and X. Wang. 2011. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3mediated pathway. Proc. Natl. Acad. Sci. USA 108: 20054-20059.
33. Kim, S. O., K. Ono, and J. Han. 2001. Apoptosis by pan-caspase inhibitors in lipopolysaccharide-activated macrophages. Am. J. Physiol. Lung Cell. Mol. Physiol. 281: L1095-L1105.
34. Oberst, A., C. P. Dillon, R. Weinlich, L. L. McCormick, P. Fitzgerald, C. Pop, R. Hakem, G. S. Salvesen, and D. R. Green. 2011. Catalytic activity of the caspase8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 471: 363-367.
35. Kaiser, W. J., and M. K. Offermann. 2005. Apoptosis induced by the Toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J. Immunol. 174: 4942-4952.
36. Bauernfeind, F. G., G. Horvath, A. Stutz, E. S. Alnemri, K. MacDonald, D. Speert, T. Fernandes-Alnemri, J. Wu, B. G. Monks, K. A. Fitzgerald, et al 2009. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J. Immunol. 183: 787-791.
37. Tenev, T., K. Bianchi, M. Darding, M. Broemer, C. Langlais, F. Wallberg, A. Zachariou, J. Lopez, M. MacFarlane, K. Cain, and P. Meier. 2011. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol. Cell 43: 432-448.
38. Feoktistova, M., P. Geserick, B. Kellert, D. P. Dimitrova, C. Langlais, M. Hupe, K. Cain, M. MacFarlane, G. Häcker, and M. Leverkus. 2011. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol. Cell 43: 449-463.
39. Dillon, C. P., A. Oberst, R. Weinlich, L. J. Janke, T. B. Kang, T. Ben-Moshe, T. W. Mak, D. Wallach, and D. R. Green. 2012. Survival function of the FADDCASPASE-8-cFLIP(L) complex. Cell Rep. 1: 401-407.
40. Frelin, C., V. Imbert, V. Bottero, N. Gonthier, A. K. Samraj, K. SchulzeOsthoff, P. Auberger, G. Courtois, and J. F. Peyron. 2008. Inhibition of the NF-kappaB survival pathway via caspase-dependent cleavage of the IKK complex scaffold protein and NF-kappaB essential modulator NEMO. Cell Death Differ. 15: 152-160.
41. Dudgeon, C., P. Wang, X. Sun, R. Peng, Q. Sun, J. Yu, and L. Zhang. 2010. PUMA induction by FoxO3a mediates the anticancer activities of the broadrange kinase inhibitor UCN-01. Mol. Cancer Ther. 9: 2893-2902.
42. Manns, J., M. Daubrawa, S. Driessen, F. Paasch, N. Hoffmann, A. Löffler, K. Lauber, A. Dieterle, S. Alers, T. Iftner, et al 2011. Triggering of a novel intrinsic apoptosis pathway by the kinase inhibitor staurosporine: activation of caspase-9 in the absence of Apaf-1. FASEB J. 25: 3250-3261.
43. Sagulenko, V., S. J. Thygesen, D. P. Sester, A. Idris, J. A. Cridland, P. R. Vajjhala, T. L. Roberts, K. Schroder, J. E. Vince, J. M. Hill, et al 2013. AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic death pathways via ASC. Cell Death Differ. 20: 1149-1160.
44. Pierini, R., C. Juruj, M. Perret, C. L. Jones, P. Mangeot, D. S. Weiss, and T. Henry. 2012. AIM2/ASC triggers caspase-8-dependent apoptosis in Francisella-infected caspase-1-deficient macrophages. Cell Death Differ. 19: 1709-1721.
45. Kang, T. B., S. H. Yang, B. Toth, A. Kovalenko, and D. Wallach. 2013. Caspase8 blocks kinase RIPK3-mediated activation of the NLRP3 inflammasome. Immunity 38: 27-40.
46. Minotti, G., P. Menna, E. Salvatorelli, G. Cairo, and L. Gianni. 2004. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56: 185-229.
47. Fulda, S., and D. Vucic. 2012. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 11: 109-124.
48. Jin, Z., Y. Li, R. Pitti, D. Lawrence, V. C. Pham, J. R. Lill, and A. Ashkenazi. 2009. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137: 721-735.
49. Labbé, K., C. R. McIntire, K. Doiron, P. M. Leblanc, and M. Saleh. 2011. Cellular inhibitors of apoptosis proteins cIAP1 and cIAP2 are required for efficient caspase-1 activation by the inflammasome. Immunity 35: 897-907.
50. Rathinam, V. A., S. K. Vanaja, L. Waggoner, A. Sokolovska, C. Becker, L. M. Stuart, J. M. Leong, and K. A. Fitzgerald. 2012. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by Gram-negative bacteria. Cell 150: 606-619.
51. Takahashi, N., L. Duprez, S. Grootjans, A. Cauwels, W. Nerinckx, J. B. DuHadaway, V. Goossens, R. Roelandt, F. Van Hauwermeiren, C. Libert, et al. 2012. Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis. 3: e437.
52. Barenholz, Y. 2012. Doxil - the first FDA-approved nano-drug: lessons learned. J. Control. Release 160: 117-134.
53. Ali, I., Rahis-Uddin, K. Salim, M. A. Rather, W. A. Wani, and A. Haque. 2011. Advances in nano drugs for cancer chemotherapy. Curr. Cancer Drug Targets 11: 135-146.
54. Apetoh, L., F. Ghiringhelli, A. Tesniere, A. Criollo, C. Ortiz, R. Lidereau, C. Mariette, N. Chaput, J. P. Mira, S. Delaloge, et al. 2007. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 220: 47-59.
55. Tang, D., R. Kang, C. W. Cheh, K. M. Livesey, X. Liang, N. E. Schapiro, R. Benschop, L. J. Sparvero, A. A. Amoscato, K. J. Tracey, et al 2010. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 29: 5299-5310.
56. Lamkanfi, M., A. Sarkar, L. Vande Walle, A. C. Vitari, A. O. Amer, M. D. Wewers, K. J. Tracey, T. D. Kanneganti, and V. M. Dixit. 2010. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J. Immunol. 185: 4385-4392.
57. Lu, B., T. Nakamura, K. Inouye, J. Li, Y. Tang, P. Lundbäck, S. I. Valdes-Ferrer, P. S. Olofsson, T. Kalb, J. Roth, et al 2012. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488: 670-674.
58. Brenchley, J. M., and D. C. Douek. 2012. Microbial translocation across the GI tract. Annu. Rev. Immunol. 30: 149-173.
59. van Vliet, M. J., H. J. Harmsen, E. S. de Bont, and W. J. Tissing. 2010. The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog. 6: e1000879.
60. Kroemer, G., L. Galluzzi, O. Kepp, and L. Zitvogel. 2013. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31: 51-72.
61. Zitvogel, L., O. Kepp, L. Galluzzi, and G. Kroemer. 2012. Inflammasomes in carcinogenesis and anticancer immune responses. Nat. Immunol. 13: 343-351.